Obsidian Therapeutics, Inc. has filed a report detailing a change in ownership involving Mark L. Reisenauer. This filing, submitted on November 13, 2026, is significant as it underscores the company's commitment to transparency and governance within the pharmaceutical preparations industry.

Background

Obsidian Therapeutics, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company trades under the ticker symbol OBX on the Nasdaq exchange. As a smaller reporting company and an emerging growth entity, Obsidian aims to innovate within the life sciences field. Recent filings include a Form 10-Q and an 8-K, indicating ongoing activity and developments.

What the Filing Says

The recent filing, accession number 0001104659-26-127194, indicates that Mark L. Reisenauer is now recognized as a director of the company. The filing states, "no securities owned: 1," which suggests a formal reporting of ownership status. This change is part of a broader strategy to ensure compliance with SEC regulations.

Impact

This change may affect various stakeholders, including shareholders and employees, by potentially influencing company strategy and direction. As a director, Reisenauer's decisions could shape the company's future initiatives and partnerships in the competitive pharmaceutical landscape.

What's Next

The filing does not say what happens next.

Details of the Ownership Change

Mark L. Reisenauer's appointment as a director is officially recorded in the filing under the reporting owner section, which confirms his identity and relationship to the company. Notably, the filing specifies that he does not hold any additional securities beyond the single share reported, indicating a minimal ownership stake at this time.

Company Background and Address

Obsidian Therapeutics, Inc. is headquartered at 1030 Massachusetts Avenue, Cambridge, MA 02138. This location is significant as it situates the company within a prominent biotech hub, which may facilitate collaborations and partnerships within the life sciences sector.

Power of Attorney

The filing also includes a Power of Attorney document, executed on November 10, 2026, which designates several individuals, including Gabriela Morales-Rivera, as attorneys-in-fact for Reisenauer. This document grants them the authority to execute forms and take necessary actions related to his duties as a director, ensuring compliance with SEC regulations.

Absence of Financial Information

While the filing provides important updates regarding ownership and governance, it does not include any financial performance metrics or projections for Obsidian Therapeutics, Inc. This absence leaves stakeholders without insights into the company's current financial health or future outlook.